Envision Healthcare $106 million exchange offer
Davis Polk advised the dealer manager in connection with the private offer by Envision Healthcare Corporation to exchange approximately $106 million of its new first-lien senior secured…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Aeglea BioTherapeutics $138 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and pre-funded warrants offering by Aeglea, including the full exercise…
Biogen $3 billion senior notes offering
Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.250% senior notes due 2030…
Akeso HK$2.44 billion IPO
Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…
Coherus BioSciences $200 million convertible notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…
Natera $287.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc. of $287.5 million aggregate principal amount of its 2.25%…
Nevro $346 million concurrent offerings of stock and convertible senior notes
Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189.75 million aggregate principal amount of its 2.75% convertible…
InnoCare Pharma HK$2.24 billion IPO
Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…
Cigna $3.5 billion senior notes offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of $1.5 billion aggregate principal amount of 2.400% senior notes due…
Kala Pharmaceuticals $126.2 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 16,000,000 shares of common stock…